Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

Get a high-probability setup with clear entry and exit points right here. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the risk of cardiovascular events. Now the Danish company is hoping to score ...

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory. Investors ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

It has been estimated that 90% of medical device waste consists of single-use products or components, so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...